Skip to Content

Posts tagged with "Drug Assays"

  • Drug Assays

    Nematodes And Your Compounds

    Here’s an update on the research in Ethan Perlstein’s lab, in which he raises an interesting question. When you screen against some sort of purified protein, you’re optimizing on potency, but not necessarily on many other properties (except perhaps, at some level, solubility in the buffer system). But a cell-based screen for an in… Read More
  • Chemical News

    Screen Carefully

    This recent paper asks the question “Can Invalid Bioactives Undermine Natural-Product Based Drug Discovery?” And as any of you who’ve done any natural product screening can attest, the answer is “You betcha”. There are any number of natural products (here’s one!) that, although active in a given screening assay,… Read More
  • Chemical News

    One Step Beyond! Maybe More.

    There are plenty of useful drugs whose structures are, well, odd-looking. Antibiotics, as a class, have a lot of these: macrocycles, polyenes, polyhydroxylated beasts that don’t fit in with a medicinal chemist’s ideas of what a reasonable compound should look like. The “Rule of Five” metrics have been debated endlessly for w… Read More
  • Chemical Biology

    The Boston DNA Encoded Library Conference

    As mentioned, I’m attending the first Boston symposium on encoded library platforms today. I’m starting this post, which I’ll update during the day as interesting things come up. I thought I’d do a quick introduction to the ideas behind this technology, for those who haven’t been following the field. (That link above a… Read More
  • Drug Assays

    Pattern-Matching Binding Sites

    Here’s a recent paper that bears on the “How many binding pockets are there” question. Or maybe that’s the “How many different types of binding pockets” question, which last came up around here a couple of years ago. That one was a computational approach that suggested that there were around 500 different varieti… Read More
  • Drug Assays

    Not Quite There Yet

    I’ve been meaning to blog about this paper, because its abstract certainly promises a lot: . . .Target prediction software based on machine learning models correctly identified additional macromolecular targets of the computationally designed compound and the structurally related marketed drug azosemide. The study validates computational de n… Read More
  • Drug Assays

    The Latest on Encoded Screening Libraries

    I wanted to mention an upcoming meeting, for people in the Boston/Cambridge area, on DNA-encoded library technologies – Friday, November 6, at AstraZeneca’s site in Waltham. I’ll be helping moderate a panel discussion at the end of the meeting, but there are speakers during the day from Harvard (David Liu) as well as AstraZeneca,… Read More
  • Chemical News

    Cheap, Diverse, Accessible, and Novel: Not All at the Same Time

    There was a comment here the other day from someone asking how to get ahold of some less-well-trampled chemical matter to run a screen against. That question (which I would assume is coming from an academic lab) has several implications, so I thought I’d discuss some of them. There are commercial screening collections out there… Read More
  • Chemical News

    The “Dark Matter” of a Compound Collection

    An awful lot of drug discovery comes down (sooner or later) to screening compound collections. This has been true for a long time now, and it doesn’t look like it’s going away, either. So with that in mind, what’s in your collection? Did you buy a bunch of stuff from the vendors to fill it… Read More
  • Biological News

    Crowding Proteins to Make Them Perform

    The inside of a vial is not like the inside of a cell. That’s something that we don’t always think about while running assays, but it’s certainly true. Not many places, truth be told, are quite like the inside of a cell. It’s crowded in there. for starters, with all sorts of proteins, macromolecules, and… Read More